Claritas Gaining Global Rights to R-107, Varied Nitric Oxide PAH Therapy

Claritas Gaining Global Rights to R-107,  Varied Nitric Oxide PAH Therapy

292704

Claritas Gaining Global Rights to R-107, Varied Nitric Oxide PAH Therapy

Claritas Pharmaceuticals has signed a letter of intent with the Salzman Group to acquire exclusive global rights to develop and market R-107 — a liquid form of nitric oxide — to treat, and possibly reverse, pulmonary arterial hypertension (PAH). The agreement is expected to come into effect by May 15, pending regulatory approval. Nitric oxide, a gas naturally found in the body, works as an antiviral, fighting off viruses. Claritas — previously known as Kalytera Therapeutics —…

You must be logged in to read/download the full post.